Analysts Set Immunic, Inc. (NASDAQ:IMUX) PT at $6.00

Shares of Immunic, Inc. (NASDAQ:IMUX) have received a consensus rating of “Buy” from the nine ratings firms that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, six have issued a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $6.1667.

IMUX has been the topic of several recent analyst reports. upgraded shares of Immunic to a “strong-buy” rating in a report on Tuesday, February 3rd. Guggenheim began coverage on shares of Immunic in a research note on Tuesday. They issued a “buy” rating and a $7.00 target price for the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Immunic in a research report on Monday, December 29th. D. Boral Capital decreased their price target on shares of Immunic from $8.00 to $4.00 and set a “buy” rating for the company in a report on Friday, February 13th. Finally, HC Wainwright dropped their price objective on shares of Immunic from $8.00 to $5.00 and set a “buy” rating on the stock in a report on Monday, March 2nd.

Immunic Price Performance

Immunic stock opened at $1.32 on Monday. The stock has a market capitalization of $172.21 million, a price-to-earnings ratio of -1.89 and a beta of 1.46. Immunic has a 1-year low of $0.51 and a 1-year high of $1.51. The business has a fifty day moving average price of $0.92 and a 200-day moving average price of $0.80.

Immunic (NASDAQ:IMUX) last announced its earnings results on Thursday, February 26th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.02). On average, equities research analysts anticipate that Immunic will post -0.94 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Immunic

A number of institutional investors and hedge funds have recently modified their holdings of IMUX. Nantahala Capital Management LLC acquired a new position in Immunic in the 4th quarter worth approximately $2,337,000. Millennium Management LLC lifted its stake in Immunic by 544.6% during the 4th quarter. Millennium Management LLC now owns 3,419,299 shares of the company’s stock valued at $1,825,000 after acquiring an additional 2,888,829 shares during the period. Laurion Capital Management LP boosted its holdings in shares of Immunic by 106.3% in the 4th quarter. Laurion Capital Management LP now owns 3,882,162 shares of the company’s stock valued at $2,072,000 after acquiring an additional 2,000,000 shares during the last quarter. Marshall Wace LLP boosted its holdings in shares of Immunic by 91.2% in the 4th quarter. Marshall Wace LLP now owns 1,019,983 shares of the company’s stock valued at $541,000 after acquiring an additional 486,468 shares during the last quarter. Finally, Connective Capital Management LLC acquired a new stake in shares of Immunic in the fourth quarter worth $161,000. Institutional investors and hedge funds own 51.82% of the company’s stock.

Immunic Company Profile

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.